We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$102B
AUM Growth
+$1.43B
(+1.4%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
32.54%
Holding
287
New
14
Increased
80
Reduced
134
Closed
11
Avg Time Held
2.7
years
Top 10 Avg Time Held
3
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qiagen
QGEN
|
+$518M |
| 2 |
AstraZeneca
AZN
|
+$246M |
| 3 |
Alkermes
ALKS
|
+$172M |
| 4 |
Whirlpool
WHR
|
+$94.4M |
| 5 |
Eli Lilly
LLY
|
+$78.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QGENF
QIAGEN NV
QGENF
|
+$534M |
| 2 |
Charles Schwab
SCHW
|
+$265M |
| 3 |
Amgen
AMGN
|
+$235M |
| 4 |
NVIDIA
NVDA
|
+$233M |
| 5 |
Microsoft
MSFT
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.82% |
| 2 | Healthcare | 22.95% |
| 3 | Industrials | 16.78% |
| 4 | Consumer Discretionary | 9.51% |
| 5 | Financials | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
DELISTED
Paramount Global Class B
PARA
| $17.2M | 0.02% |
+270,000
| New | +$16M |
2016 Q4
0 quarters
|
|
202
Mercury Insurance
MCY
$5.64B
| $17M | 0.02% |
281,600
| – | – |
2013 Q2
14 quarters
|
|
203
Public Service Enterprise Group
PEG
$35B
| $16.3M | 0.02% |
372,379
| – | – |
2013 Q2
14 quarters
|
|
|
TUES
204
DELISTED
Tuesday Morning Corp
TUES
| $15.2M | 0.01% |
2,812,900
-1,104,985
| -28% | -$5.94M |
2013 Q2
14 quarters
|
|
205
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
| $15.1M | 0.01% |
627,000
-500
| -0.1% | -$12.1K |
2015 Q3
5 quarters
|
|
206
Herc Holdings
HRI
$4.15B
| $14.9M | 0.01% |
369,992
+49,900
| +16% | +$1.8M |
2016 Q3
1 quarter
|
|
|
TVIA
207
DELISTED
TerraVia Holdings, Inc. Common Stock
TVIA
| $14.5M | 0.01% |
12,608,921
+1,013,312
| +9% | +$1.84M |
2016 Q2
2 quarters
|
|
208
C.H. Robinson
CHRW
$16.8B
| $14.4M | 0.01% |
196,400
-410,079
| -68% | -$29.7M |
2013 Q2
14 quarters
|
|
|
OMED
209
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $13.9M | 0.01% |
1,800,700
+498,000
| +38% | +$4.58M |
2013 Q3
13 quarters
|
|
|
POT
210
DELISTED
Potash Corp Of Saskatchewan
POT
| $13.5M | 0.01% |
744,700
-4,452,100
| -86% | -$77.2M |
2013 Q2
14 quarters
|
|
211
Mastercard
MA
$540B
| $13.4M | 0.01% |
129,800
+75,700
| +140% | +$7.84M |
2013 Q2
14 quarters
|
|
212
Signet Jewelers
SIG
$4.53B
| $12.9M | 0.01% |
+136,700
| New | +$12M |
2016 Q4
0 quarters
|
|
213
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
| $12.8M | 0.01% |
598,877
+17,000
| +3% | +$344K |
2016 Q3
1 quarter
|
|
214
Ciena
CIEN
$50.6B
| $12.6M | 0.01% |
517,470
-1,700
| -0.3% | -$37.1K |
2013 Q2
14 quarters
|
|
215
OraSure Technologies
OSUR
$263M
| $11.1M | 0.01% |
1,262,000
-753,900
| -37% | -$6.22M |
2013 Q2
14 quarters
|
|
216
Digimarc Corp
DMRC
$151M
| $10.6M | 0.01% |
353,000
+49,000
| +16% | +$1.53M |
2015 Q3
5 quarters
|
|
217
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $10.5M | 0.01% |
670,000
+10,000
| +2% | +$156K |
2013 Q4
12 quarters
|
|
218
DELISTED
Immunogen Inc
IMGN
| $10.3M | 0.01% |
5,052,943
-4,566,179
| -47% | -$9.17M |
2013 Q2
14 quarters
|
|
|
ESL
219
DELISTED
Esterline Technologies
ESL
| $10.1M | 0.01% |
113,331
| – | – |
2013 Q4
12 quarters
|
|
220
Arbutus Biopharma
ABUS
$850M
| $9.64M | 0.01% |
3,935,000
+65,200
| +2% | +$190K |
2015 Q1
7 quarters
|
|
221
ExxonMobil
XOM
$718B
| $9.59M | 0.01% |
106,200
-669,312
| -86% | -$58.5M |
2013 Q2
14 quarters
|
|
222
Constellium
CSTM
$3.45B
| $9.16M | 0.01% |
1,552,400
-46,800
| -3% | -$286K |
2014 Q4
8 quarters
|
|
223
Axon Enterprise
AXON
$33.9B
| $8.97M | 0.01% |
370,000
+135,000
| +57% | +$3.33M |
2016 Q2
2 quarters
|
|
|
SIOX
224
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $8.94M | 0.01% |
89,938
-2,662
| -3% | -$280K |
2015 Q2
6 quarters
|
|
225
Greif
GEF
$4.55B
| $8.72M | 0.01% |
170,000
-20,400
| -11% | -$1.04M |
2013 Q2
14 quarters
|
|
Similar funds
Primecap Management's Q4 2016 Portfolio in Review
As of Q4 2016, Primecap Management held 287 positions worth $102B, up 1.4% from $100B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Primecap Management's Q4 2016 filing shows 14 new, 80 increased, 134 reduced and 11 closed positions. Its largest new stake was Qiagen: 17,384,319 shares worth $536M. The largest sale was QIAGEN NV, an estimated $534M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 30% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q4 2016 buy was Qiagen: 17,384,319 shares worth $536M.
- Primecap Management added most to AstraZeneca in Q4 2016, an estimated $246M increase.
- Primecap Management's biggest Q4 2016 reduction was Charles Schwab, cutting an estimated $265M.
- Primecap Management fully exited QIAGEN NV in Q4 2016, selling an estimated $534M.
- Primecap Management's ten largest holdings make up 33% of its $102B portfolio in Q4 2016.
- Primecap Management opened 14 new positions and closed 11 in Q4 2016.
- Primecap Management's portfolio value rose 1.4% quarter-over-quarter to $102B.
Based on Primecap Management's 13F filing for Q4 2016, filed 13 Feb 2017.